1990s - OUR OSMOTIN-RICH SUPERPLANTS
One such lab in a leading agricultural Italian University focused on the daunting task of bionegineering Osmotin-rich olive trees and kiwi vines, as these plant varieties are among Italy's principal exports, with major economic, environmental, and cultural values. The research effort was led by our Chief Biotechnology Advisor Prof. Eddo Rugini, Ph.D. and our CEO Dr. Bruno Ruggiero, PhD.
Not only was the Italian team successful in the lab, but following about 10 years of R&D, the now Osmotin overexpressing super plants plants were also successfully field-tested for another 10 years, confirming their ability to thrive under drought-stress, cold stress, fungal attacks and overall having superior agronomic qualities compared to common kiwi and olive varieties.
1990s - THE DISCOVERY OF ADIPONECTIN
Meanwhile, in 1995, in a seemingly unrelated event, the human hormone Adiponectin was discovered in the adipose tissue, which gives it its name. It quickly became clear that Adiponectin could be an excellent anti-diabetes therapeutic candidate. However, as time went by, no practical way of using Adiponectin therapeutically was identified. Efforts to create a synthetic version of Adiponectin failed as well.
The human hormone Adiponectin controls metabolism.
Osmotin's and Adiponectin's 3D structures overlap allowing Osmotin to mimic Adiponectin's functions.
2004 - DR. RUGGIERO GIFTS $1 MILLION TO UNIVERSITY FOR R&D
SUPPORTING OSMOTIN RESEARCH & DEVELOPMENT
In 2004 Dr. Bruno Ruggiero provides a $1 million USD gift to Purdue University to promote research on Osmotin's human health applications.
2013 - A NEW DIMENSION
With this in mind, in 2013 Dr. Ruggiero co-founds 9th Dimension Biotech, Inc. with the goal of bringing a life-time of experience in biotech and the best technology in the field to the market with a strategic and solution-oriented approach.
As an established leading expert on both Adiponectin and Osmotin in 2016 Dr. Ruggiero was honored to receive a US Einstein visa for his work in this field. Dr. Ruggiero's guidance has allowed the Company to develop our FORZA™ supplement from the university laboratories through to a phase 2 clinical trial in partnership with leading European Hospitals and the Italian National Foundation for Multiple Sclerosis. Results from this trial are expected in early 2025.
Under his leadership, 9th Dimension Biotech has developed a powerful interdisciplinary network of relationships and collaborations with the world's leading scientists and best research institutions in pursuit of the mission to identify and develop the most promising technologies to offer quality solutions to the world's most difficult problems.
PLANTING THE SEEDS OF HUMAN HEALTH